¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen interferon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® interferon ÇÑ±Û ÀÎÅÍÆä·Ð
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ µ¿¹°ÀÇ ¼¼Æ÷¿¡¼­ »ý»êµÇ´Â Ç×¹ÙÀÌ·¯½º¼º ´Ü¹éÁú. ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ Á¶Á÷ÀÌ »ý»êÇϴ Ç×¹ÙÀÌ·¯½º ÀÛ¿ëÀ̳ª Ç×Á¾¾çÀۿ렵ý¸®È°¼ºÀÌ Àִ ´ç´Ü¹éÁúÀ» ¸»ÇÑ´Ù. 1957³â ¿µ±¹ ±¹¸³ÀÇÇבּ¸¼ÒÀÇ A.¾ÆÀÌÀÛ½º¿Í J.¸°µç¸Õ¿¡ ÀÇÇØ ¾Ë·ÁÁ³´Ù. À̵éÀº ¿­Ã³¸®ÇÑ ¹ÙÀÌ·¯½º¸¦ ´Þ°¿ ³»¸·ÀÇ ¼¼Æ÷¿¡ Ã³¸®Çϰí ÇÏ·ç µ¿¾È ¹è¾çÇÑ ´ÙÀ½, ¹è¾ç¾×À» ÃßÃâÇÏ¿© »õ·Î¿î ´Þ°¿ ³»¸·°ú ¼¯Àº ÈÄ, »ì¾Æ Àִ ¹ÙÀÌ·¯½º¸¦ Áý¾î³ÖÀº °á°ú, ¹ÙÀÌ·¯½ºÀÇ ºÐ¿­ÀÌ ¾ïÁ¦µÇ¾ú°í, ±× ¹è¾ç¾×À» ³ÖÁö ¾ÊÀº °æ¿ì¿¡´Â ¹ÙÀÌ·¯½º°¡ ºÐ¿­µÇ¾î ¹ø½ÄÇÏ¿´´Ù. ÀÌ ½ÇÇèÀÇ Àǹ̴ ¹ÙÀÌ·¯½º°¡ µ¿¹°¼¼Æ÷¿¡ Ä§ÀÔÇϸ頹æ¾îÀÇ ±â´ÉÀ¸·Î ±× µ¿¹°¼¼Æ÷´Â ÀÎÅÍÆä·ÐÀ» »ý»êÇÏ¿© ¹ÙÀÌ·¯½ºÀÇ ºÐ¿­À» ¸·´Â´Ù´Â °ÍÀÌ´Ù. Á¦ÀÏ ¸¹ÀÌ ¿¬±¸µÈ ºÐ¾ß´Â Àΰ£ÀÇ ÀÎÅÍÆä·ÐÀÌ´Ù. ÀÎÅÍÆä·ÐÀº ¹ÙÀÌ·¯½º°¨¿° ¹× ³»µ¶¼Ò Åõ¿©, ³ª¾Æ°¡¼­´Â Ç׿øÀڱؠµî¿¡ ¹ÝÀÀÇÏ¿© °®°¡Áö ¼¼Æ÷·ÎºÎÅÍ ¹æÃâµÈ´Ù. IFNÀ̶ó°í ¾à±â. ÇöÀç, 3Á¾(IFN-¥á, IFN-¥â, IFN-¥ã)ÀÌ ¾Ë·ÁÁ® ÀÖÀ¸¸ç °¢°¢ ÀǾàǰÀ¸·Î »ç¿ëµÇ°í ÀÖ´Ù.
¿µ¹® carcinoembryonic antigen ÇÑ±Û ¾Ï¹è¾ÆÇ׿ø
¼³¸í   
  ¿ø·¡ Å¾ÆÀÇ ÀåÁ¶Á÷¿¡¼­ Á¤»óÀûÀ¸·Î Á¸ÀçÇϴ ¹°Áú·Î Å¾Ʊâ ÀÌÈÄ¿¡´Â Á¸ÀçÇÏÁö ¾Ê´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª À§, °£, ÇãÆÄ µîÀÇ ¾ÏÀÌ Àִ °æ¿ì¿¡ ¼ºÀο¡¼­µµ Á¸ÀçÇÑ´Ù. À̸¦ ÀÌ¿ëÇØ¼­ ¾ÏÀÇ Ä¡·áÈ¿°ú ÆÇÁ¤À̳ª Àç¹ß¿©ºÎÀÇ Á¶»ç¿¡ ÀÌ¿ëÇÑ´Ù.
¿µ¹® antigen ÇÑ±Û Ç׿ø
¼³¸í   
  Æ¯ÀÌÇÑ ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö Àִ ¾î¶°ÇÑ ¹°Áú. ¿©±â¿¡¼­ ¸»Çϴ ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ̶õ ºñƯÀÌÀûÀΠ¸é¿ª¹ÝÀÀ°ú´Â ¹Ý´ëµÇ´Â Àǹ̷Π±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ Ç×ü³ª ±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ ¼¼Æ÷¸¦ ¸¸µå´Â °ÍÀ» ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gamma interferon
    °¨¸¶ÀÎÅÍÆä·Ð
  • immune interferon
    ¸é¿ªÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • interferon alpha
    ÀÎÅÍÆä·Ð¾ËÆÄ
  • interferon alpha-2b
    ÀÎÅÍÆä·Ð¾ËÆÄ-2b
  • interferon omega
    ÀÎÅÍÆä·Ð¿À¸Þ°¡
  • interferon receptor
    ÀÎÅÍÆä·Ð¼ö¿ëü
  • interferon tau
    ÀÎÅÍÆä·ÐŸ¿ì
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen competition
    Ç׿ø°æÀï
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • carcinoembryonic antigen
    ¾ÏÁ¾¹è¾ÆÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • sequestered antigen
    °Ý¸®Ç׿ø
  • somatic antigen
    ü¼¼Æ÷Ç׿ø, ±ÕüÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • tumor antigen
    Á¾¾çÇ׿ø
  • antigen excess
    Ç׿ø°úÀ×
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • gamma interferon
    °¨¸¶ÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • immune interferon
    ¸é¿ªÀÎÅÍÆä·Ð
  • interferon receptor
    ÀÎÅÍÆä·Ð¼ö¿ëü
  • antigen
    Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø
  • antigen competition
    Ç׿ø°æÀï
  • antigen excess
    Ç׿ø°úÀ×
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen recognition
    Ç׿øÀÎÁö
  • antigen analysis
    Ç׿øºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immune interferon (Interferon-¥ã)
    ¸é¿ªÀÎÅÍÆä·Ð (°¨¸¶ÀÎÅÍÆä·Ð)
  • ABH antigen
    ABH Ç׿ø
  • B antigen
    B Ç׿ø(ù÷ê«)
  • B cell antigen
    B ¼¼Æ÷Ç׿ø
  • CA 19-9 antigen
    CA 19-9 Ç׿ø
  • CA 50 antigen
    CA 50 Ç׿ø
  • CA-2<>
    CA-2<<ÄÝ·ÎÀ̵åÇ׿ø>>
  • CD5 antigen
    CD5 Ç׿ø
  • CEA(carcinoembryonic antigen)
    žƼº¾ÏÇ׿ø
  • Cartwright antigen
    īƮ¶óÀÌÆ®Ç׿ø
  • Cha antigen
    Cha Ç׿ø
  • Chido (Ch") antigen
    Chido(Ch") Ç׿ø
  • D antigen
    D Ç׿ø
  • D antigen
    DÇ׿ø
  • D-related antigen
    D-°ü·ÃÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immune interferon (Interferon-¥ã)
    ¸é¿ªÀÎÅÍÆä·Ð (°¨¸¶ÀÎÅÍÆä·Ð)
  • alpha (¥á)-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • beta (¥â)-interferon
    º£Å¸ÀÎÅÍÆä·Ð
  • gamma (¥ã) interferon
    °¨¸¶ÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð.
  • interferon
    ÀÎÅÍÆä·Ð
  • interferon (INF) gene
    ÀÎÅÍÆä·Ð À¯ÀüÀÚ
  • interferon (INF) receptor
    ÀÎÅÍÆä·Ð ¼ö¿ëü
  • interferon unit
    ÀÎÅÍÆä·Ð ´ÜÀ§
  • interferon, immune
    ¸é¿ªÀÎÅÍÆä·Ð (°¨¸¶ÀÎÅÍÆä·Ð)
  • interferon- a(ifn-a)
    ÀÎÅÍÆä·Ð a
  • interferon- b(ifn-b)
    ÀÎÅÍÆä·Ð b
  • interferon- g(ifn-g)
    ÀÎÅÍÆä·Ð g
  • interferon-¥á (INF-¥á)
    ¾ËÆÄÀÎÅÍÆä·Ð
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • circumsporozoite antigen
    Æ÷ÀÚ¼ÒüÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • excretory-secretory antigen
    ºÐºñ¹è¼³Ç׿ø
  • metabolic antigen
    ´ë»çÇ׿ø
  • somatic antigen
    üÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interferon
    ÀÎÅÍÆä·Ð
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen binding capacity
    Ç׿ø °áÇÕ´É(ù÷ê«Ì¿ùêÒö)
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • antigen-binding fragment
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê) Á¶°¢
  • antigen-excess zone
    Ç׿ø°úÀ× ±¸¿ª(ù÷ê«Î¦í¥Ï¡æ´)
  • Australia antigen
    ¿À½ºÆ®¶ö¸®¾Æ Ç׿ø (ù÷ê«)
  • Boivin antigen
    º¸¿Í¹æ Ç׿ø(ù÷ê«)
  • complete antigen
    ¿ÏÀüÇ׿ø(èÇîïù÷ê«)
  • conjugated antigen
    Æ÷ÇÕÇ׿ø(øÙùêù÷ê«)
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀ Ç׿ø(Îßó©Úãëëù÷ê«)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interferon
    ÀÎÅÍÆä·Ð
  • antigen
    Ç׿ø
  • antigen antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • HLA antigen
    HLAÇ׿ø
  • HLA[=human leukocyte antigen]
    HLAÇ׿ø, Àΰ£¹éÇ÷±¸Ç׿ø
  • homologous antigen
    »óµ¿Ç׿ø
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HLA histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod...
TSA technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso...
TSTA toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen...
IFN InterFeroN
INF-¥ã Interferon-¥ã
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
T-antigen Thomsen Friedenreich antigen
T-antigen Tumor antigen
IFN 1-interferon
IF 2-interferon
IFN alpha Alpha interferon
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • interferon
    ÀÎÅÍÆä·Ð
    ¹ÙÀÌ·¯½ºÀÇ RNA¿Í ´Ü¹éÁú ÇÕ¼ºÀ» ¼±ÅÃÀûÀ¸·Î ¹æÇØÇÏ´Â Ç×¹ÙÀÌ·¯½º¼º ´Ü¹éÁúÀ» °üÀåÇÏ´Â ¼¼Æ÷ À¯ÀüÀÚÀÇ Àü»ç¿¡ ÀÇÇØ »ý¼ºµÈ ¹ÙÀÌ·¯½º ºñƯÀÌÀûÀÌ°í ¼÷ÁÖ Æ¯ÀÌÀû Ç×¹ÙÀÌ·¯½º ÀÛ¿ëÀ» ³ªÅ¸³»´Â ´ç´Ü¹éÁú ±ºÀÌ´Ù. ¶ÇÇÑ ÀÎÅÍÆä·ÐÀº ¸é¿ª Á¶Àý ±â´ÉÀ» °¡Áö¸ç ºñ¹ÙÀÌ·¯½º¼º ¼¼Æ÷³» ±â»ýüÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ´Ù. ¹ÙÀÌ·¯½º °¨¿°, ƯÈ÷ ÀÌÁß¼â RNA ¹ÙÀÌ·¯½º, ¼¼Æ÷³» ±â»ýü, ¿ø»ýµ¿¹°, ¼¼±Õ·ù ¹× ¼¼±Õ »ý»ê¹° µîÀÌ ÀÎÅÍÆä·ÐÀÇ »ý»êÀ» ÀÚ±ØÇÒ ¼ö ÀÖ´Ù. ÀÎÅÍÆä·ÐÀº »ý»ê ¼¼Æ÷¿Í ±â´É¿¡ µû¶ó 3±ºÀ¸·Î ³ª´©Áö¸¸ ¸ðµç µ¿¹° ¼¼Æ÷´Â ÀÎÅÍÆä·ÐÀ» »ý»êÇÒ ¼ö ÀÖ°í, ¾î¶² ¼¼Æ÷´Â ÇÑ Á¾·ù ÀÌ»óÀ» »ý»êÇÑ´Ù.
  • accessible antigen
    Á¢±Ù °¡´É Ç׿ø, ±ÙÁ¢ Ç׿ø
  • antigen adjuvant
    Ç׿ø ¾ÆÁê¹ÝÆ®, Ç׿ø º¸°­Á¦
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen detection
    Ç׿ø °ËÃâ
  • antigen drift
    Ç׿ø¼Ò º¯ÀÌ
  • antigen excess
    Ç׿ø °úÀ×
    ħ°­ ¹ÝÀÀ µî ÃÖÀûºñ¿¡¼­ ¹ÝÀÀÀÌ Àß °üÂûµÇ´Â °æ¿ì Ç׿øÀÇ ¾çÀÌ Áö³ªÄ¡°Ô ¸¹À¸¸é ¹Ý´ë·Î ¹ÝÀÀÀÌ ¾àÇØÁö°í °üÂûÀÌ °¡´ÉÇÑ ¹ÝÀÀÀÌ »ý±æ ¶§±îÁöÀÇ ½Ã°£ÀÌ ±æ¾îÁø´Ù. ÀÌ¿Í °°ÀÌ Ç׿øÀÌ °úÀ×µÇ¾î ¹ÝÀÀÀÌ °üÂûµÇÁö ¾Ê°Ô µÇ´Â °æ¿ì Ç׿ø °úÀ׿¡ ÀÇÇÑ ¹ÝÀÀÀÇ ¾ïÁ¦Çϰí ÇÑ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â Ç׿ø °úÀ×ÀÎ °æ¿ì¿¡´Â °¡¿ë¼ºÀÌ µÈ´Ù.
  • antigen mimicry
    Ç׿ø À¯»ç¼º
  • antigen presentation
    Ç׿ø Á¦°ø, Ç׿ø Àü´Þ, Ç׿ø Á¦½Ã
  • antigen processing
    Ç׿ø ó¸®
    Ç׿øÀÌ Ç׿ø Á¦½Ã ¼¼Æ÷¿¡ ÀÇÇÏ¿© Æ÷ÃËµÇ°í ³ª¼­ B ¼¼Æ÷, T ¼¼Æ÷¿¡ Ç׿øÀÌ Á¦½ÃµÇ±â±îÁöÀÇ °úÁ¤À» ¸»ÇÑ´Ù. ÀÌ °úÁ¤¿¡´Â Ç׿øÀÇ Å½½Ä, Ç׿øÀÇ ´ÜÆíÈ­ ȤÀº Ç׿ø °áÁ¤±â±îÁöÀÇ ºÐÇØ 󸮰¡ Æ÷ÇԵȴÙ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
alpha interferon <cytokine> Interferon which is released by leukocytes in response to a viral infection. A protein cytokine that is used as an anticancer agent.
(15 Nov 1997)
beta interferon A protein liberated by fibroblasts in response to a viral infection.
(27 Sep 1997)
receptors, interferon Specific molecular sites or structures on or in cells with which interferons react or to which they bind in order to modify the function of the cells. Interferons exert their pleiotropic effects through two different receptors. Alpha- and beta-interferon crossreact with common receptors, while gamma-interferon initiates its biological effects through its own specific receptor system.
(12 Dec 1998)
immune interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
interferon <cytokine> A family of glycoproteins derived from human cells which normally has a role in fighting viral infections by preventing virus multiplication in cells.
They are secreted by vertebrate cells in response to a wide variety of inducers and confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions.
Interferon-alpha is made by leucocytes and interferon-gamma by fibroblasts after viral infection. Interferon-alpha and -beta are also called type I interferons, interferon-gamma as Type II interferons, more usually classed as cytokines.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
interferon-alpha <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products.
It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia.
A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents.
See: interferon-alpha 2a, interferon-alpha 2b
Synonym: leukocyte interferon.
Pharmacological action: antineoplastic agent, antiviral agent.
(20 Sep 2002)
interferon-alpha 2a <cytokine> Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-alphaA (human leukocyte protein moiety reduced)
(12 Dec 1998)
interferon-alpha 2b <chemical> Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon-b2 <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas.
It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate.
An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow.
Acronym: IL-6
(12 Dec 1998)
interferon-beta <cytokine> One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
Synonym: fibroblast interferon.
Pharmacological action: adjuvants, immunologic, antineoplastic agent, antiviral agents.
Chemical name: Interferon-alphaB (human leukocyte protein moiety reduced)
(12 Dec 1998)
interferon-gamma <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
interferon inducers Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers poly a-u and poly I-c. Viruses, bacteria, and protozoa have been also known to induce interferons.
(12 Dec 1998)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interferon
    ÀÎÅÍÆä·Ð(¹ÙÀÌ·¯½º Áõ½Ä ¾ïÁ¦ ¹°Áú)
  • HY antigen
    H-YÇ׿ø(Y¿°»öü À¯ÀüÀÚ¿¡ ÀÇÁ¸ÇÏ´Â Á¶Á÷ ÀûÇÕ Ç׿ø)
  • Rhesus factor(antigen)
    =RH FACTOR
  • antigen
    Ç׿ø(Ç÷¾×Áß¿¡ antibodyÀÇ Çü¼ºÀ» ÃËÁøÇÏ´Â ¹°Áú)
  • histiocompatibility antigen
    Á¶Á÷ ÀûÇÕ¼º Ç׿ø
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á